Literature DB >> 3091770

Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography.

K L Leenders, A J Palmer, N Quinn, J C Clark, G Firnau, E S Garnett, C Nahmias, T Jones, C D Marsden.   

Abstract

L-[18F] fluorodopa was administered in trace amounts intravenously to healthy control subjects and to patients with Parkinson's disease. Striatal uptake of radioactivity was measured using positron emission tomography. The capacity of the striatum to retain tracer was severely impaired in patients compared to controls. This may reflect a reduction of striatal dopamine storage in Parkinson's disease. Patients showing the "on/off" phenomenon had an even greater decrease of striatal storage capacity.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3091770      PMCID： PMC1028944          DOI： 10.1136/jnnp.49.8.853

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  19 in total

1.  Intracerebral dopamine metabolism studied by a novel radioisotope technique.

Authors:  G Firnau; E S Garnett; P K Chan; L W Belbeck
Journal:  J Pharm Pharmacol       Date:  1976-07       Impact factor: 3.765

2.  Blood-brain barrier transport and cerebral utilization of dopa in living monkeys.

Authors:  E S Garnett; G Firnau; C Nahmias; S Sood; L Belbeck
Journal:  Am J Physiol       Date:  1980-05

3.  A new autoradiographic approach for imaging forebrain dopamine distribution.

Authors:  G F Wooten; M K Horne
Journal:  Ann Neurol       Date:  1982-08       Impact factor: 10.422

Review 4.  Positron emission tomography of the brain: new possibilities for the investigation of human cerebral pathophysiology.

Authors:  K L Leenders; J M Gibbs; R S Frackowiak; A A Lammertsma; T Jones
Journal:  Prog Neurobiol       Date:  1984       Impact factor: 11.685

5.  3-O-methyldopa blocks dopa metabolism in rat corpus striatum.

Authors:  A Reches; S Fahn
Journal:  Ann Neurol       Date:  1982-09       Impact factor: 10.422

6.  ECAT: a new computerized tomographic imaging system for positron-emitting radiopharmaceuticals.

Authors:  M E Phelps; E J Hoffman; S C Huang; D E Kuhl
Journal:  J Nucl Med       Date:  1978-06       Impact factor: 10.057

7.  Dopamine visualized in the basal ganglia of living man.

Authors:  E S Garnett; G Firnau; C Nahmias
Journal:  Nature       Date:  1983 Sep 8-14       Impact factor: 49.962

8.  Effects of 3-OM-dopa on monoamine metabolism in rat brain.

Authors:  J J Gervas; V Muradás; E Bazán; E G Aguado; J G de Yébenes
Journal:  Neurology       Date:  1983-03       Impact factor: 9.910

9.  Evaluation of Parkinson's disease.

Authors:  A Lieberman; M Dziatolowski; G Gopinathan; M Kupersmith; A Neophytides; J Korein
Journal:  Adv Biochem Psychopharmacol       Date:  1980

10.  The site of dopamine formation in rat striatum after L-dopa administration.

Authors:  F Hefti; E Melamed; R J Wurtman
Journal:  J Pharmacol Exp Ther       Date:  1981-04       Impact factor: 4.030
View more
  54 in total

1.  Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson's disease.

Authors:  J O Rinne; H Ruottinen; J Bergman; M Haaparanta; P Sonninen; O Solin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-12       Impact factor: 10.154

Review 2.  Levodopa-induced response fluctuations in patients with Parkinson's disease: strategies for management.

Authors:  Teus van Laar
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 3.  The on-off phenomenon.

Authors:  A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

Review 4.  PET and movement disorders.

Authors:  D J Brooks; R S Frackowiak
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

Review 5.  Neuroimaging methods applied in Parkinson's disease.

Authors:  Klaus L Leenders
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

Review 6.  Tracers for metabolic imaging of brain and heart. Radiochemistry and radiopharmacology.

Authors:  G Stöcklin
Journal:  Eur J Nucl Med       Date:  1992

7.  Asymmetry of substantia nigra neuronal loss in Parkinson's disease and its relevance to the mechanism of levodopa related motor fluctuations.

Authors:  P A Kempster; W R Gibb; G M Stern; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-01       Impact factor: 10.154

8.  Disease progression continues in patients with advanced Parkinson's disease and effective subthalamic nucleus stimulation.

Authors:  R Hilker; A T Portman; J Voges; M J Staal; L Burghaus; T van Laar; A Koulousakis; R P Maguire; J Pruim; B M de Jong; K Herholz; V Sturm; W-D Heiss; K L Leenders
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-09       Impact factor: 10.154

9.  Assessment of dopamine metabolism in brain of patients with dementia by means of 18F-fluorodopa and PET.

Authors:  M Itoh; K Meguro; T Fujiwara; J Hatazawa; R Iwata; K Ishiwata; T Takahashi; T Ido; H Sasaki
Journal:  Ann Nucl Med       Date:  1994-11       Impact factor: 2.668

10.  The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.

Authors:  Fulvio Bracco; Angelo Battaglia; Carlos Chouza; Erik Dupont; Oscar Gershanik; Jose Felix Marti Masso; Jean-Louis Montastruc
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.